PRDX5

Summary

PRDX5 (peroxiredoxin 5, HGNC:9355) is a protein-coding gene on chromosome 11q13.1, encoding Peroxiredoxin-5, mitochondrial (P30044). Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively.

This gene encodes a member of the peroxiredoxin family of antioxidant enzymes, which reduce hydrogen peroxide and alkyl hydroperoxides. The encoded protein interacts with peroxisome receptor 1 and plays an antioxidant protective role in different tissues under normal conditions and during inflammatory processes. The use of alternate transcription start sites is thought to result in transcript variants that use different in-frame translational start codons to generate isoforms that are targeted to the mitochondrion (isoform L) or peroxisome/cytoplasm (isoform S). Multiple related pseudogenes have been defined for this gene.

Source: NCBI Gene 25824 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 60 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_012094

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9355
Approved symbol	PRDX5
Name	peroxiredoxin 5
Location	11q13.1
Locus type	gene with protein product
Status	Approved
Aliases	ACR1, AOEB166, MGC142285, PRXV, PMP20, B166, PRDX6, PLP, SBBI10, MGC117264, MGC142283
Ensembl gene	ENSG00000126432
Ensembl biotype	protein_coding
OMIM	606583
Entrez	25824

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 18 protein_coding

ENST00000265462, ENST00000347941, ENST00000352435, ENST00000877454, ENST00000877455, ENST00000877456, ENST00000877457, ENST00000926912, ENST00000926913, ENST00000926914, ENST00000926915, ENST00000926916, ENST00000926917, ENST00000926918, ENST00000926919, ENST00000926920, ENST00000926921, ENST00000964952

RefSeq mRNA: 5 — MANE Select: NM_012094 NM_001358511, NM_001358516, NM_012094, NM_181651, NM_181652

CCDS: CCDS8069, CCDS8070, CCDS8071

Canonical transcript exons

ENST00000265462 — 6 exons

Exon	Start	End
ENSE00000992394	64321007	64321068
ENSE00001195244	64321586	64321811
ENSE00001265861	64318121	64318386
ENSE00001291509	64320661	64320792
ENSE00001313724	64320865	64320903
ENSE00001317366	64319734	64319868

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 99.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 163.1450 / max 677.4886, expressed in 1828 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
114951	153.6536	1828
114952	9.1924	1729
114950	0.2990	129

Top tissues by expression

263 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	99.82	gold quality
epithelium of nasopharynx	UBERON:0001951	99.75	gold quality
bronchus	UBERON:0002185	99.75	gold quality
nasopharynx	UBERON:0001728	99.73	gold quality
palpebral conjunctiva	UBERON:0001812	99.67	gold quality
right uterine tube	UBERON:0001302	99.64	gold quality
mucosa of transverse colon	UBERON:0004991	99.55	gold quality
apex of heart	UBERON:0002098	99.54	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.54	gold quality
right adrenal gland	UBERON:0001233	99.48	gold quality
right lobe of thyroid gland	UBERON:0001119	99.46	gold quality
esophagus squamous epithelium	UBERON:0006920	99.46	gold quality
right adrenal gland cortex	UBERON:0035827	99.46	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.43	gold quality
left lobe of thyroid gland	UBERON:0001120	99.42	gold quality
prefrontal cortex	UBERON:0000451	99.41	gold quality
cerebellar cortex	UBERON:0002129	99.41	gold quality
cerebellar hemisphere	UBERON:0002245	99.41	gold quality
left adrenal gland	UBERON:0001234	99.40	gold quality
anterior cingulate cortex	UBERON:0009835	99.39	gold quality
hypothalamus	UBERON:0001898	99.38	gold quality
right frontal lobe	UBERON:0002810	99.38	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.37	gold quality
left adrenal gland cortex	UBERON:0035825	99.37	gold quality
germinal epithelium of ovary	UBERON:0001304	99.36	gold quality
adenohypophysis	UBERON:0002196	99.35	gold quality
pituitary gland	UBERON:0000007	99.33	gold quality
thyroid gland	UBERON:0002046	99.33	gold quality
gingival epithelium	UBERON:0001949	99.31	gold quality
cerebellum	UBERON:0002037	99.31	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-HCAD-15	yes	4642.08
E-CURD-114	yes	3590.38
E-MTAB-6819	yes	1398.31
E-HCAD-1	yes	75.53
E-MTAB-8410	yes	25.36
E-GEOD-125970	yes	22.71
E-GEOD-130148	yes	15.37
E-MTAB-7316	yes	10.88
E-HCAD-9	yes	8.20
E-MTAB-10042	yes	7.74
E-MTAB-9801	yes	6.58
E-MTAB-10596	no	1014.07
E-GEOD-139324	no	446.57
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): DEK, GABPA, GATA1, NRF1, ZNF85

miRNA regulators (miRDB)

11 targeting PRDX5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-7847-3P	96.63	64.58	952

Literature-anchored findings (GeneRIF, showing 40)

• crystal structure at 1.5 angstrom resolution (PMID:11518528)
• Glutaredoxin-dependent peroxiredoxin from poplar: protein-protein interaction and catalytic mechanism (PMID:11832487)
• the expression of peroxiredoxin 5 is upregulated in osteoarthritis (PMID:12417342)
• multiple subcellular targeting of peroxiredoxin 5 in mammalian cells can be implicated in antioxidant protective mechanisms under nonpathological conditions (PMID:14732291)
• Transfection of PRXVI protects immortalized human WI-38 and murine NIH3T3 fibroblasts against cytotoxic doses of tert-butylhydroperoxide and H2O2 (PMID:14741336)
• new crystal form of human peroxiredoxin 5 is described at 2.0 A resolution; under initial reducing conditions, one chain remains oxidized and forms an homodimer with a symmetry-related one through intermolecular disulfide bonds between Cys47 and Cys151 (PMID:15046979)
• plays a protective role in human tendon cells against oxidative stress by reducing apoptosis and maintaining collagen synthesis (PMID:15276323)
• Human peroxiredoxin 5 is also a peroxynitrite reductase. (PMID:15280035)
• nuclear PrxV associates with coilin-containing bodies suggesting possible interaction of this protein with transcription complexes (PMID:15304327)
• The level of expression is directly correlated with the functional status of epithelial cells, being higher in multinodular goiters, and even more pronounced in hyperthyroid tissues, such as Graves’ disease. (PMID:15785239)
• mitochondrial peroxiredoxin 5 may play an important role in mitochondrial genome stability (PMID:15848167)
• these findings suggest that PrxV is a multifunctional protein, which is essential for protection against apoptosis induced by anticancer drugs. (PMID:16781710)
• Together, these results suggest that constitutively expressed PRDX5 gene plays an important role in protecting the genome against oxidation and may also be involved in the control of transcription of noncoding DNA. (PMID:16817890)
• expression in white matter from normal human brain and MS patients (PMID:17623739)
• we present new alternative splicing variants encoded specifically by human PRDX5 gene. The characterization of human PRDX5 gene revealed complexity of its regulation & high variability of sequences that might be associated with pathological situations. (PMID:17628720)
• kinetic analysis of human peroxiredoxin 5 (PMID:17892856)
• Peroxiredoxin V (PRXV) is an important antioxidant protein of lung epithelial cells. Its expression in the human lung increases in inflammation. (PMID:18219526)
• Our results show that mitochondrial PRDX-depleted cells are more prone to oxidative damages and apoptosis induced by MPP(+), a complex I inhibitor which provides an experimental paradigm of Parkinson’s disease. (PMID:18262354)
• Significantly decreased expression of Prx-2, -3, and -5 in FED may suggest an alteration in the ability of endothelial cells to withstand oxidant-induced damage and may be closely related to the pathogenesis of this disease. (PMID:18378575)
• report here three crystal forms in which this intramolecular disulfide bond is indeed observed. The structures are characterized by the expected local unfolding of the peroxidatic loop, but also by the unfolding of the resolving loop (PMID:18489898)
• Ets regulates PRDX5 expression through their interaction with HGMB1 protein. (PMID:19016754)
• analysis of fragment molecules that bind the human peroxiredoxin 5 active site (PMID:20305821)
• basal expression of the human PRDX5 gene is regulated by GABP (PMID:20937353)
• The promoter region critical for Prx5 gene regulation to which the novel negative transcription regulator, GATA1 binds in human breast cancer cell lines. (PMID:22020876)
• This study demonistrated that overexpression of mitochondrial PRDX5 protects SH-SY5Y cells against the ROS/RNS-dependent neuronal death induced by MPP+. (PMID:23216451)
• PRX5 is either consumed or its production is impaired in severe stroke (PMID:24385276)
• show here how the ligand-observed saturation transfer difference (STD) experiment and the PRDX5 protein-observed 15N-HSQC experiment, two popular NMR screening experiments, can be used to compare the binding modes of analogous fragments (PMID:25025339)
• peroxisomal PRDX5 protects oligodendrocytes against peroxisomal and mitochondrial oxidative stress. (PMID:25772011)
• Results found that Prx5 was increased in the cellular model of Alzheimer’s disease (AD) and, identify a role for Prx5 as an upregulator of Cdk5 activation via reactive oxygen species-mediated Ca2+-mediated calpain activation. (PMID:28358580)
• The PRX5 can be used as a predictive biomarker and serves as a putative therapeutic target for the development of clinical treatments for human CRC. (PMID:28431931)
• High PRX5 expression is associated with gastric cancer. (PMID:28535004)
• Single-molecule experiments demonstrate that PRDX5 specifically binds to TLR4. PRDX5 binding induces a cellular mechanoresponse. (PMID:29551349)
• These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients. (PMID:30104402)
• human Prx3 rapidly reduces peroxynitrite; Prx3 intrinsic fluorescence presents biphasic changes upon oxidation;Peroxynitrite in excess leads to Prx3 nitration and hyperoxidation;Both Prx3 and Prx5 are predicted to be main targets for mitochondrial peroxynitrite. (PMID:30391677)
• Studied association of expression levels of peroxiredoxin 5 (PRDX5) and survival in ovarian cancer patients. (PMID:30756364)
• Prx V regulates colon cancer cell apoptosis via scavenging ROS cellular levels and mediating the Wnt/beta-catenin signaling pathway, which was induced by beta-lapachone. (PMID:31262894)
• Prx V suppresses AGS cell apoptosis via scavenging intracellular ROS and modulating apoptosis-related markers. (PMID:31280208)
• the role of a key metabolic integrator coenzyme A (CoA) in modulating the activity of Prdx5 was investigated. (PMID:31375973)
• Upregulated expression of Prdx3 and Prdx5 has been reported in different cancer types involving their association with different factors, such as transcription factors, micro RNAs, tumor suppressors, response elements, and oncogenic genes. Also, increased production of Prdx3 and Prdx5 is associated with the development of chemoresistance in certain types of cancers and it leads to further complications. [review] (PMID:31500275)
• Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. (PMID:31505325)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	prdx5	ENSDARG00000055064
mus_musculus	Prdx5	ENSMUSG00000024953
rattus_norvegicus	Prdx5	ENSRNOG00000021125
drosophila_melanogaster	Prx5	FBGN0038570

Protein

Protein identifiers

Peroxiredoxin-5, mitochondrial — P30044 (reviewed: P30044)

Alternative names: Alu corepressor 1, Antioxidant enzyme B166, Liver tissue 2D-page spot 71B, PLP, Peroxiredoxin V, Peroxisomal antioxidant enzyme, TPx type VI, Thioredoxin peroxidase PMP20, Thioredoxin-dependent peroxiredoxin 5

All UniProt accessions (1): P30044

UniProt curated annotations — full annotation on UniProt →

Function. Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events.

Subunit / interactions. Monomer.

Subcellular location. Mitochondrion Cytoplasm. Peroxisome matrix.

Tissue specificity. Widely expressed.

Post-translational modifications. S-palmitoylated. Palmitoylation occurs on the active site, inhibiting its reactivity; therefore PRDX5 palmitoylation status determines its antioxidant capacity. S-palmitoylated. Depalmitoylated by ABHD10.

Miscellaneous. The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this atypical 2-Cys Prx, C(R) is present in the same subunit to form an intramolecular disulfide. The disulfide is subsequently reduced by thioredoxin. Produced by alternative splicing.

Similarity. Belongs to the peroxiredoxin family. Prx5 subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
P30044-1	Mitochondrial	yes
P30044-2	Cytoplasmic+peroxisomal
P30044-3	3
P30044-4	4

RefSeq proteins (5): NP_001345440, NP_001345445, NP_036226, NP_857634, NP_857635 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013740	Redoxin	Domain
IPR013766	Thioredoxin_domain	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR037944	PRX5-like	Family

Pfam: PF08534

Enzyme classification (BRENDA):

• EC 1.11.1.24 — thioredoxin-dependent peroxiredoxin (BRENDA: 72 organisms, 110 substrates, 31 inhibitors, 72 Km, 50 kcat entries)

Substrate kinetics (BRENDA)

13 substrates with measured Km, best-characterized 13. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
H2O2	0.0004–11.7	23
CUMENE HYDROPEROXIDE	0.0066–0.191	8
THIOREDOXIN	0.001–0.0794	7
TERT-BUTYL HYDROPEROXIDE	—	5
THIOREDOXIN A	0.0009–0.0122	5
THIOREDOXIN B	0.0022–0.0208	5
T-BUTYL HYDROPEROXIDE	0.072–0.193	4
THIOREDOXIN Q	0.0007–0.0028	4
REDUCED THIOREDOXIN	0.0024–0.004	2
REDUCED THIOREDOXIN A	0.0079–0.0087	2
ETHYL HYDROPEROXIDE	0.0045	1
LINOLEIC ACID HYDROPEROXIDE	0.117	1
TRYPAREDOXIN 2	0.0319	1

Catalyzed reactions (Rhea), 1 shown:

• a hydroperoxide + [thioredoxin]-dithiol = an alcohol + [thioredoxin]-disulfide + H2O (RHEA:62620)

UniProt features (43 total): helix 10, strand 8, modified residue 6, splice variant 3, mutagenesis site 3, turn 3, sequence variant 2, transit peptide 1, chain 1, lipid moiety-binding region 1, disulfide bond 1, domain 1, sequence conflict 1, short sequence motif 1, active site 1

Structure

Experimental structures (PDB)

12 structures.

PDB	Method	Resolution (Å)
3MNG	X-RAY DIFFRACTION	1.45
4MMM	X-RAY DIFFRACTION	1.47
1HD2	X-RAY DIFFRACTION	1.5
1URM	X-RAY DIFFRACTION	1.7
2VL3	X-RAY DIFFRACTION	1.83
2VL2	X-RAY DIFFRACTION	1.93
1H4O	X-RAY DIFFRACTION	1.95
4K7O	X-RAY DIFFRACTION	1.98
1OC3	X-RAY DIFFRACTION	2
4K7I	X-RAY DIFFRACTION	2.25
4K7N	X-RAY DIFFRACTION	2.3
2VL9	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30044-F1	86.13	0.76

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 100 (cysteine sulfenic acid (-soh) intermediate)

Post-translational modifications (7): 182, 100, 75, 83, 83, 116, 171

Disulfide bonds (1): 100–204

Mutagenesis-validated functional residues (3):

Position	Phenotype
100	loss of antioxidant activity. loss of s-palmitoylation.
125	no change in antioxidant activity. no change in s-palmitoylation levels.
204	loss of antioxidant activity. no change in s-palmitoylation levels.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-3299685	Detoxification of Reactive Oxygen Species
R-HSA-5628897	TP53 Regulates Metabolic Genes

MSigDB gene sets: 483 (showing top): MODULE_172, MODULE_93, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, MODY_HIPPOCAMPUS_POSTNATAL, REACTOME_INNATE_IMMUNE_SYSTEM, HNF3ALPHA_Q6, GOBP_INFLAMMATORY_RESPONSE, GOBP_POSITIVE_REGULATION_OF_RNA_SPLICING, GOCC_SECRETORY_GRANULE, GOBP_POSITIVE_REGULATION_OF_MRNA_PROCESSING, MODULE_151, GOBP_HYDROGEN_PEROXIDE_CATABOLIC_PROCESS, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_III, HSIAO_HOUSEKEEPING_GENES

GO Biological Process (13): inflammatory response (GO:0006954), response to oxidative stress (GO:0006979), negative regulation of transcription by RNA polymerase III (GO:0016480), positive regulation of collagen biosynthetic process (GO:0032967), cellular response to oxidative stress (GO:0034599), cellular response to reactive oxygen species (GO:0034614), hydrogen peroxide catabolic process (GO:0042744), negative regulation of apoptotic process (GO:0043066), cell redox homeostasis (GO:0045454), negative regulation of oxidoreductase activity (GO:0051354), regulation of apoptosis involved in tissue homeostasis (GO:0060785), reactive nitrogen species metabolic process (GO:2001057), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (11): RNA polymerase III transcription regulatory region sequence-specific DNA binding (GO:0001016), peroxidase activity (GO:0004601), signaling receptor binding (GO:0005102), thioredoxin peroxidase activity (GO:0008379), antioxidant activity (GO:0016209), identical protein binding (GO:0042802), cysteine-type endopeptidase inhibitor activity involved in apoptotic process (GO:0043027), peroxynitrite reductase activity (GO:0072541), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), thioredoxin-dependent peroxiredoxin activity (GO:0140824)

GO Cellular Component (12): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), cytoplasm (GO:0005737), mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), peroxisome (GO:0005777), peroxisomal matrix (GO:0005782), cytosol (GO:0005829), cytoplasmic vesicle (GO:0031410), intracellular membrane-bounded organelle (GO:0043231), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cellular response to chemical stress	1
Transcriptional Regulation by TP53	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	4
cellular anatomical structure	3
regulation of apoptotic process	2
protein binding	2
intracellular membrane-bounded organelle	2
intracellular anatomical structure	2
defense response	1
response to stress	1
regulation of transcription by RNA polymerase III	1
transcription by RNA polymerase III	1
negative regulation of DNA-templated transcription	1
positive regulation of biosynthetic process	1
positive regulation of collagen metabolic process	1
collagen biosynthetic process	1
regulation of collagen biosynthetic process	1
response to oxidative stress	1
cellular response to chemical stress	1
response to reactive oxygen species	1
cellular response to oxidative stress	1
cellular response to oxygen-containing compound	1
catabolic process	1
hydrogen peroxide metabolic process	1
apoptotic process	1
negative regulation of programmed cell death	1
cellular homeostasis	1
oxidoreductase activity	1
negative regulation of catalytic activity	1
regulation of oxidoreductase activity	1
tissue homeostasis	1
homeostasis of number of cells within a tissue	1
metabolic process	1
cellular detoxification	1
transcription cis-regulatory region binding	1
antioxidant activity	1
oxidoreductase activity, acting on peroxide as acceptor	1
thioredoxin-dependent peroxiredoxin activity	1
molecular_function	1
cellular oxidant detoxification	1
cysteine-type endopeptidase regulator activity involved in apoptotic process	1
peroxidase activity	1

Protein interactions and networks

STRING

2538 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRDX5	PRDX1	P35703	908
PRDX5	TXN	P10599	828
PRDX5	PRDX3	P30048	825
PRDX5	STX17	P56962	784
PRDX5	PRDX4	Q13162	770
PRDX5	SOD1	P00441	762
PRDX5	PRDX2	P31945	748
PRDX5	PRDX6	P30041	679
PRDX5	SESN2	P58004	678
PRDX5	F5H3C5	F5H3C5	646
PRDX5	SOD2	P04179	646
PRDX5	TXN2	Q99757	642
PRDX5	GLRX	P35754	642
PRDX5	ULBP3	Q9BZM4	642
PRDX5	SRXN1	Q9BYN0	627

IntAct

90 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SOD1	PRDX5	psi-mi:“MI:0915”(physical association)	0.610
PRDX5	NUFIP2	psi-mi:“MI:0915”(physical association)	0.560
PRDX5	SMCP	psi-mi:“MI:0915”(physical association)	0.560
PRDX5	CDKN2D	psi-mi:“MI:0915”(physical association)	0.560
SOD1	GAPDH	psi-mi:“MI:0914”(association)	0.500
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
SCRIB	PRDX5	psi-mi:“MI:0407”(direct interaction)	0.440
PRDX5	PRDX5	psi-mi:“MI:0407”(direct interaction)	0.440
YJU2	PRDX5	psi-mi:“MI:0915”(physical association)	0.400
PRDX5	DCAF10	psi-mi:“MI:0915”(physical association)	0.400
	AGPS	psi-mi:“MI:0915”(physical association)	0.400
ERBB2	PRDX5	psi-mi:“MI:0915”(physical association)	0.370
ERBB3	PRDX5	psi-mi:“MI:0915”(physical association)	0.370
ERBB4	PRDX5	psi-mi:“MI:0915”(physical association)	0.370
SIRT4	VWA8	psi-mi:“MI:0914”(association)	0.350
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
LIN54	HDAC3	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
SHLD3		psi-mi:“MI:0914”(association)	0.350
SOD1	NPEPPSL1	psi-mi:“MI:0914”(association)	0.350
SOD1	PGK1	psi-mi:“MI:0914”(association)	0.350

BioGRID (215): PRDX5 (Affinity Capture-MS), DUT (Co-fractionation), NME1 (Co-fractionation), PARK7 (Co-fractionation), PRDX1 (Co-fractionation), PRDX2 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation), PRDX5 (Co-fractionation)

ESM2 similar proteins: A9PCL4, G0S1P8, O08709, O14313, O22711, O35244, O43099, O69777, O77834, P0A251, P0A252, P0A862, P0A863, P0A864, P0A865, P0A866, P0AE08, P0AE09, P0AE10, P0AE11, P30041, P30044, P32119, P35704, P44758, P52572, P57668, P57880, P73728, P99029, Q2KJE4, Q2PFL9, Q5ASN8, Q5R7E0, Q61171, Q6W8Q2, Q8K3U7, Q8KED5, Q8XVP0, Q8Z7A8

Diamond homologs: A9PCL4, B3EWI1, G0S1P8, O14313, O22711, O43099, O69777, P14292, P14293, P30044, P38013, P44758, P56577, P56578, P73728, P99029, Q01116, Q53212, Q5ASN8, Q69TY4, Q7F8S5, Q7G959, Q949U7, Q9BGI1, Q9FR35, Q9GLW7, Q9GLW9, Q9M7T0, Q9R063, Q9SDD6, Q9SRZ4, Q9XEX2, Q9Y8B8, P0A1P8, P0A1P9, P0AC62, P0AC63, P0AC64, P68688, P68689

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DEK	“down-regulates quantity by repression”	PRDX5	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 97 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
mRNA stabilization	5	21.6×	2e-03
hematopoietic progenitor cell differentiation	5	14.0×	4e-03
response to ethanol	8	13.8×	1e-04
wound healing	5	13.4×	4e-03
transcription by RNA polymerase II	8	6.6×	4e-03
response to xenobiotic stimulus	8	6.5×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	37
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
814137	GRCh37/hg19 1q24.2-25.1(chr1:167430471-174635618)x1	Pathogenic

SpliceAI

892 predictions. Top by Δscore:

Variant	Effect	Δscore
11:64318323:A:T	donor_gain	1.0000
11:64319864:CCAAG:C	donor_loss	1.0000
11:64319869:G:GA	donor_loss	1.0000
11:64319870:T:A	donor_loss	1.0000
11:64320859:CTGCA:C	acceptor_loss	1.0000
11:64320860:TGCA:T	acceptor_loss	1.0000
11:64320861:GCAG:G	acceptor_loss	1.0000
11:64320862:CAGGT:C	acceptor_loss	1.0000
11:64320863:A:C	acceptor_loss	1.0000
11:64320902:AGG:A	donor_loss	1.0000
11:64320903:GGT:G	donor_loss	1.0000
11:64321002:CTTA:C	acceptor_loss	1.0000
11:64321005:A:AC	acceptor_loss	1.0000
11:64321005:A:AG	acceptor_gain	1.0000
11:64321005:AG:A	acceptor_gain	1.0000
11:64321006:G:GT	acceptor_gain	1.0000
11:64321006:GG:G	acceptor_gain	1.0000
11:64321006:GGA:G	acceptor_gain	1.0000
11:64321006:GGAGA:G	acceptor_gain	1.0000
11:64321066:G:GT	donor_gain	1.0000
11:64321066:GAG:G	donor_gain	1.0000
11:64318185:G:GT	donor_gain	0.9900
11:64318196:G:GT	donor_gain	0.9900
11:64319728:TTCTA:T	acceptor_loss	0.9900
11:64319729:TCTA:T	acceptor_loss	0.9900
11:64319731:TA:T	acceptor_loss	0.9900
11:64319732:AGGT:A	acceptor_gain	0.9900
11:64319732:AGGTG:A	acceptor_gain	0.9900
11:64319733:GGT:G	acceptor_gain	0.9900
11:64319733:GGTG:G	acceptor_gain	0.9900

AlphaMissense

1358 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:64319848:T:C	F96L	0.997
11:64319850:C:A	F96L	0.997
11:64319850:C:G	F96L	0.997
11:64320765:G:C	W137C	0.997
11:64320765:G:T	W137C	0.997
11:64320763:T:A	W137R	0.995
11:64320763:T:C	W137R	0.995
11:64320748:T:C	F132L	0.994
11:64320750:T:A	F132L	0.994
11:64320750:T:G	F132L	0.994
11:64321659:A:C	S205R	0.994
11:64321661:C:A	S205R	0.994
11:64321661:C:G	S205R	0.994
11:64319834:G:A	G91E	0.993
11:64320676:T:C	F108L	0.992
11:64320678:T:A	F108L	0.992
11:64320678:T:G	F108L	0.992
11:64320741:T:A	N129K	0.992
11:64320741:T:G	N129K	0.992
11:64320743:A:T	D130V	0.992
11:64321587:T:C	F181L	0.992
11:64321589:C:A	F181L	0.992
11:64321589:C:G	F181L	0.992
11:64320664:C:G	H104D	0.991
11:64320727:T:C	C125R	0.991
11:64319860:T:C	C100R	0.990
11:64320733:A:C	S127R	0.990
11:64320735:T:A	S127R	0.990
11:64320735:T:G	S127R	0.990
11:64320742:G:C	D130H	0.990

dbSNP variants (sampled 300 via entrez): RS1000039151 (11:64317749 C>T), RS1000505630 (11:64320113 A>G), RS1002157591 (11:64318958 G>A,C,T), RS1002492776 (11:64318856 G>A,C,T), RS1002531308 (11:64319295 C>T), RS1002959093 (11:64322038 G>A), RS1003125682 (11:64320487 T>A), RS1003482317 (11:64318111 C>A,G,T), RS1003549748 (11:64317152 G>A,T), RS1003850845 (11:64317977 T>C), RS1004089110 (11:64319511 A>G), RS1004462251 (11:64316157 CGT>C), RS1004474345 (11:64321265 C>A,T), RS1004505828 (11:64320952 T>C), RS1004621084 (11:64321001 T>C)

Disease associations

OMIM: gene MIM:606583 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST000719_6	Alopecia areata	4.000000e-07
GCST000879_54	Crohn’s disease	6.000000e-10
GCST001622_1	Sarcoidosis	3.000000e-18
GCST003268_10	Psoriasis vulgaris	2.000000e-09
GCST003599_1	Systemic lupus erythematosus	8.000000e-09
GCST003599_5	Systemic lupus erythematosus	3.000000e-13
GCST004132_98	Crohn’s disease	5.000000e-06
GCST004785_38	Vitiligo	5.000000e-08
GCST004866_21	Alopecia areata	9.000000e-14
GCST005527_14	Psoriasis	2.000000e-06
GCST005531_3	Multiple sclerosis	2.000000e-09
GCST006585_2541	Blood protein levels	9.000000e-33
GCST007994_27	Asthma (age of onset)	5.000000e-09
GCST007995_27	Asthma (childhood onset)	2.000000e-11
GCST009131_3	Systemic sclerosis	5.000000e-09
GCST009597_169	Multiple sclerosis	1.000000e-11
GCST010988_259	Adult body size	4.000000e-08
GCST011991_5	Psoriasis or type 2 diabetes (trans-disease meta-analysis)	1.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:1001494	psoriasis vulgaris

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3627586 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	4
Tobacco Smoke Pollution	decreases expression, affects expression	3
Decitabine	affects expression, increases expression	2
Arsenic Trioxide	increases expression, affects cotreatment, affects reaction	2
Acetaminophen	affects cotreatment, decreases expression	2
Quercetin	affects cotreatment, increases expression	2
Tretinoin	affects cotreatment, affects reaction, increases expression	2
Thapsigargin	decreases expression, increases reaction, increases expression	2
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
2,2’-methylenebis(4-methyl-6-tert-butylphenol)	affects expression, affects response to substance	1
sodium arsenate	decreases expression	1
titanium dioxide	increases expression	1
pyrogallol 1,3-dimethyl ether	decreases expression, affects cotreatment, affects localization	1
decabromobiphenyl ether	decreases expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	increases expression	1
W 7	decreases reaction, increases expression	1
tetrabromobisphenol A	decreases expression	1
cerous chloride	affects cotreatment, increases expression	1
lanthanum chloride	increases expression, affects cotreatment	1
caffeic acid	increases reaction, decreases expression	1
cyfluthrin	decreases expression	1
4-methoxycinnamate methyl ester	decreases expression, increases reaction	1
chloropicrin	affects expression	1
gambierol	affects cotreatment, decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	decreases reaction, increases abundance, increases expression	1

ChEMBL screening assays

10 unique, capped per target: 10 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3630278	Binding	Binding affinity to human PRDX5 expressed in Escherichia coli at ligand/protein ratio 120 measured over 0.5 to 4 secs by STD NMR spectrometric analysis	Ligand-Orientation Based Fragment Selection in STD NMR Screening. — J Med Chem

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1Q0	Abcam K-562 PRDX5 KO	Cancer cell line	Female
CVCL_D7FY	Ubigene 22Rv1 PRDX5 KO	Cancer cell line	Male
CVCL_TG53	HAP1 PRDX5 (-) 1	Cancer cell line	Male
CVCL_TG54	HAP1 PRDX5 (-) 2	Cancer cell line	Male
CVCL_WQ37	Abcam Jurkat PRDX5 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.